


National seminar

Chimeric antigen receptor T-cell therapy

30 September 2020

Copenhagen, Denmark



Preliminary programme

Welcome

- Henrik Frederiksen, Deputy Chair, DCCC Scientific Council and Chair, Danish Society of Hematology

Current indications and the near future

- Childhood cancer by Marianne Ifversen, Consultant, Department of Pediatrics, Rigshospitalet
- Leukaemia by Søren Lykke Petersen, Danish Acute Leukemia Group and Consultant, Dep. of Haematology, Rigshospitalet
- Lymphoma by Judit Jørgensen, chair, Danish Lymphoma Group and Consultant, Dep. of Haematology, Aarhus University Hospital
- Multiple Myeloma by Anne Kærsgaard Mylin, Danish Multiple Myeloma Study Group, Speciality Registrar, Dep. of Haematology, Rigshospitalet
- Danish research in CD19 – status and perspectives by Inge Marie Svane, MD, Professor, Director, Center for Cancer Immune Therapy (CCIT-DK)
- Establishing the infrastructure needed to deliver cellular therapy (*preliminary title*) by Torben Barrington, Professor, Centre for Cellular Immunotherapy of Haematological Cancer, Department of Clinical Immunology, Odense University Hospital

How to closer link the distribution of specialised hospital services and the use of new medicines in the Danish healthcare system

- CAR-T and the planning of the distribution of specialised hospital services within the Danish Health Authority by Helene Bilsted Probst, Head of Centre – Planning, Danish Health Authority
- The use of new medicines and correlations to planning of the distribution of specialised hospital services by Jørgen Schøler Kristensen, chair, The Danish Medicines Council

Networking and refreshments

Video presentations

Perspectives: Learnings from broader clinical settings


- CAR T cell therapy for paediatric ALL: challenges and future perspectives by Professor Persis Amrolia, Great Ormond Street Hospital (GOSH) & UCL Professor of Transplantation Immunology at the Institute of Child Health
- Questions
- Key learnings from the UCL CAR T-cell programme and treatment of adult patients with ALL and lymphoma by Dr Maeve O'Reilly, Consultant Haematologist – CAR-T cell therapy & Bone marrow transplantation, University College London
- Questions

National seminar

Chimeric antigen receptor T-cell therapy

30 September 2020

Copenhagen, Denmark



Video presentations

Perspectives: Commercial and clinical-grade CAR-T-cells

- Clinical-grade CAR T-cell manufacture and correlations within research, industry and hospitals by Dr Juliana Dias Alves Pinto, Department of Haematology, University College London Hospitals
- Questions
- CAR T-cells – Swedish experiences by Gunilla Enblad, Distinguished Professor at Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology, Uppsala University
- Questions

Discussion and concluding remarks

- Per Jørgensen, MD, Deputy Chief Executive, Rigshospitalet
- Kim Brixen, MD, Professor, Deputy Chief Executive, Odense University Hospital and Svendborg Hospital
- Claus Thomsen, MD, Chief Medical Officer, Aarhus University Hospital